Fate Therapeutics Inc Interim Phase 1 Clinical Data for NHL Programs Call Transcript
Good afternoon. This is Scott Wolchko, President and CEO of Fate Therapeutics, and thank you all for joining us. We are excited to share with you today interim Phase I clinical data for FT516 and FT506 off-the-shelf, iPS-derived NK cell programs in relapsed refractory B-cell lymphoma.
Please note, as we discuss our FT516 and 596 programs today, our comments will include forward-looking statements that involve risks and uncertainties. These risks and uncertainties are detailed in our SEC filings, and I refer you to our most recent Form 10-Q filed with the SEC for full disclosure of these factors. Note that undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change.
Joining me on today's call are Dr. Wayne Chu, our Senior Vice President of Clinical Development; Dr. Sarah Cooley, our Senior Vice President of Clinical Translation; and Dr. Bob Valamehr, our Chief Research
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |